{
    "clinical_study": {
        "@rank": "3447", 
        "arm_group": [
            {
                "arm_group_label": "001", 
                "arm_group_type": "Experimental", 
                "description": "Topiramate Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.\nOL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months."
            }, 
            {
                "arm_group_label": "002", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and efficacy of topiramate in\n      adolescents with manic or mixed episodes of Bipolar I Disorder."
        }, 
        "brief_title": "A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder", 
        "completion_date": {
            "#text": "April 2002", 
            "@type": "Actual"
        }, 
        "condition": [
            "Bipolar Disorder", 
            "Affective Disorders, Psychotic", 
            "Mood Disorders", 
            "Mental Disorders"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Affective Disorders, Psychotic", 
                "Mental Disorders", 
                "Psychotic Disorders", 
                "Bipolar Disorder", 
                "Mood Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a 4-week study to evaluate the safety and effectiveness of topiramate compared to\n      placebo in the treatment of Bipolar I Disorder with an optional 6-month open-label (OL)\n      extension for qualified patients following completion of the study. On Days 1-28 patients\n      will receive placebo or topiramate 2x/day by mouth except for the 1st and last doses which\n      will be a single evening dose and a single morning dose, respectively. Study drug will be\n      titrated in 100-mg increments to 400 mg/day and patients maintained on a stable dose through\n      Day 28. During the OL extension phase, topiramate will be titrated over 5 days to 200\n      mg/day. After Day 7, topiramate may be tapered down to 100 mg/day or up to 600 mg/day, as\n      clinically indicated."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  DSM-IV diagnosis of Bipolar I Disorder (confirmed by the Kiddie-Schedule for\n             Affective Disorders and Schizophrenia-Present and Lifetime version [K-SADS-P/L])\n\n          -  YMRS score greater than or equal to 20\n\n          -  General good health as determined by medical history, physical examination, and\n             laboratory evaluations\n\n          -  Ability to swallow tablets\n\n          -  Patient's parent or guardian must be fully capable of monitoring the patient's\n             disease process and compliance to treatment\n\n          -  Parent(s) or legal guardian(s) must read and sign the informed consent form after the\n             nature of the study has been fully explained and assent must be obtained from\n             patients\n\n        Exclusion Criteria:\n\n          -  DSM-IV Axis I disorder diagnoses of autistic disorder, schizophrenia, schizoaffective\n             disorder, or other psychotic disorders not otherwise specified (NOS)\n\n          -  DSM-IV diagnosis of alcohol or substance dependence, with the exception of nicotine\n             or caffeine dependence, within the 3 months prior to baseline. Acute or intermittent\n             substance abuse prior to screening will not be exclusionary, depending upon the\n             clinical judgment of the investigator\n\n          -  Chronic antidepressant treatment within 4 weeks of randomization (5 weeks for\n             fluoxetine), use of psychostimulants in the 7 days prior to baseline, use of any\n             other psychotropic medications within 3 days or 5 half-lives, whichever is less,\n             prior to baseline, or requirement for treatment with other psychotropic drugs on an\n             ongoing basis\n\n          -  Weight less than 33 kg or current or past history of anorexia nervosa\n\n          -  Serious or unstable medical or neurological conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": {
            "#text": "13", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 6, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00035802", 
            "org_study_id": "CR016867", 
            "secondary_id": "TOPMAT-PDMD-009"
        }, 
        "intervention": [
            {
                "arm_group_label": "001", 
                "description": "Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.\nOL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months.", 
                "intervention_name": "Topiramate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "002", 
                "description": "Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Central Nervous System Agents", 
                "Topiramate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Bipolar", 
            "Mania", 
            "Pediatric", 
            "Children", 
            "Adolescent", 
            "Topiramate", 
            "Anticonvulsants", 
            "Central Nervous System Agents", 
            "Protective Agents", 
            "Neuroprotectiive Agents"
        ], 
        "lastchanged_date": "June 23, 2011", 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Multicenter, Placebo-Controlled 4-Week Study of the Safety and Efficacy of Topiramate in Adolescents With Acute Manic or Mixed Episodes of Bipolar I Disorder, With an Optional 6-Month Open-Label Extension", 
        "overall_official": {
            "affiliation": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", 
            "last_name": "Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_outcome": {
            "measure": "Change from baseline in total Young Mania Rating Scale (YMRS) score", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Day 28 (or last available observation prior to Day 28)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00035802"
        }, 
        "responsible_party": {
            "name_title": "SR DIRECTOR CLINICAL LEADER", 
            "organization": "Johnson & Johnson Pharmaceutical Research and Development, L.L.C."
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in Clinical Global Impression Scale (CGI-S) score", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 28 (or last available observation prior to Day 28)."
            }, 
            {
                "measure": "Change from baseline in Children's Global Assessment Scale (C-GAS) score", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 28 (or last available observation prior to Day 28)."
            }, 
            {
                "measure": "The number of patients continuing to meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for manic or mixed episodes of Bipolar I Disorder", 
                "safety_issue": "No", 
                "time_frame": "Day 28 (or last available observation prior to Day 28)"
            }
        ], 
        "source": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2011"
    }, 
    "geocoordinates": {}
}